(Total Views: 314)
Posted On: 07/17/2018 7:59:11 AM
Post# of 72440
The CoreRx agreement for Drug Product production aligns with one signed in April with another leading CDMO to, in parallel, bulk produce a commercial-grade supply of Brilacidin. Both of these manufacturing agreements serve to prepare for, and expedite, Brilacidin’s continued clinical development. Brilacidin is a defensin-mimetic drug candidate with unique immunomodulatory, anti-inflammatory, and antibacterial properties.
Evonik
https://www.ipharminc.com/press-release/2018/...in?rq=evon
CoreRx
https://www.ipharminc.com/press-release/2018/...achet-form
Interesting indeed.
Evonik
https://www.ipharminc.com/press-release/2018/...in?rq=evon
CoreRx
https://www.ipharminc.com/press-release/2018/...achet-form
Interesting indeed.
(4)
(0)Scroll down for more posts ▼
